Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-04-28 Annual Report
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
2018年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2018 annual report summary of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It contains detailed financial data, business overview, acquisitions, operational and R&D activities, and other comprehensive information typical of an annual report. The presence of audited financial statements, accounting data over multiple years, and extensive business discussion confirms it is a full annual report rather than a brief announcement or a regulatory filing. The document length (15,000 characters) and content depth further support this classification. Therefore, the document is classified as an Annual Report (10-K). FY 2018
2019-04-28 Chinese
2018年度财务决算报告
Annual Report Classification · 95% confidence The document is titled '2018 年度财务决算报告' which translates to '2018 Annual Financial Settlement Report'. It contains detailed financial statements including balance sheet, income statement, cash flow statement, and notes, as well as an auditor's report from a certified accounting firm. The document provides comprehensive financial data for the full fiscal year 2018, including revenue, profit, assets, liabilities, and equity. The presence of audited financial statements and detailed financial analysis indicates this is a full annual report rather than a brief announcement or a certification. The document length is 3516 characters, which is relatively short but contains substantive financial data and analysis, not just a notice or announcement. Therefore, it fits the definition of an Annual Report (10-K). FY 2018
2019-04-28 Chinese
2018年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2018 年度募集资金存放与使用情况专项报告" which translates to "2018 Annual Report on the Storage and Use of Raised Funds." It details the amount of funds raised, their management, usage, and specific investment projects funded by these raised funds. It includes detailed financial figures, investment progress, and regulatory compliance statements. The document is comprehensive and contains substantive financial data related to the use of capital raised by the company. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital usage. It is not an announcement of a report but the report itself, and it is not a general annual report or earnings release. Therefore, the appropriate classification is CAP with high confidence.
2019-04-28 Chinese
独立董事关于第四届董事会第二十二次会议等相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion report from independent directors regarding the company's board meeting and related matters for the fiscal year 2018. It discusses asset impairment provisions, profit distribution plans, external guarantees, use of raised funds, internal control self-evaluation, securities investment, and related party transactions. The document references compliance with regulatory guidelines and internal company rules but does not contain full financial statements or comprehensive financial performance data. It is a formal opinion on specific governance and financial matters related to the board meeting rather than a full annual report or audit report. The document length is 2775 characters, which is relatively short and focused on independent directors' opinions on board meeting agenda items and related disclosures. This fits best under Board/Management Information (MANG), as it relates to board meeting opinions and governance matters rather than a full report or announcement of voting results.
2019-04-28 Chinese
第四届监事会第二十二次会议会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Kangzhi Pharmaceutical Co., Ltd. It details the approval of various reports and proposals related to the company's 2018 annual financials, internal control, profit distribution, and the 2019 first quarter report. The document itself does not contain the full financial statements or detailed financial data but rather summarizes the resolutions passed and refers readers to the full reports published on the official disclosure website (cninfo.com.cn). The document length is 3142 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of meeting resolutions and report approvals, not the reports themselves. Therefore, the appropriate classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like Annual Report (10-K) or Interim Report (IR).
2019-04-28 Chinese
关于2018年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2018 annual profit distribution plan of Kangzhi Pharmaceutical Co., Ltd. It includes details about the proposed cash dividend per share, the total dividend amount, and the approval status by the board and supervisory committee. The document does not contain full financial statements or comprehensive financial performance data but rather focuses on the dividend proposal and related approvals. The document length is short (1125 characters) and it is an announcement of a dividend plan, not the full annual report or earnings release. Therefore, it fits best under the category of Notice of Dividend Amount (DIV).
2019-04-28 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.